WASHINGTON -- An investigational non-surgical treatment led to a "robust" complete response rate in patients with recurrent, low-grade non-muscle-invasive bladder cancer, the phase III ENVISION study ...
The current standard of care for high-risk superficial bladder cancer is intravesical bacillus Calmette–Guérin (BCG). Electromotive mitomycin has also shown efficacy against high-risk superficial ...
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today ...
Phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of BCG-refractory non-muscle-invasive bladder cancer. A gene expression signature associated with sensitivity to ...
INTRAVESICAL INSTILLATION of cytotoxic chemotherapy or immunotherapy is used to treat existing tumors, reduce or postpone tumor recurrence, and delay or prevent tumor progression and subsequent ...
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, ...
PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, ...
In recent years the management of non-muscle-invasive bladder cancer has undergone radical changes. Intravesical Bacillus Calmette-Guérin (BCG) has long been established as the therapeutic standard ...
Neoadjuvant mitomycin C showed a favorable safety profile with mild to moderate side effects, including hematuria, dysuria, and itchy scalp. The trial did not show significant improvement in 12-month ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results